STOCK TITAN

Hologic Inc - HOLX STOCK NEWS

Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.

Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.

Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.

Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.

Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.

Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.

Rhea-AI Summary

Hologic, Inc. (NASDAQ: HOLX) will present at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 9:10 a.m. Eastern Time in Boston, MA. The conference runs from March 6-8 and includes various presentations and panel discussions on the health care industry. Hologic's presentation will be available via a live webcast on the company's investor website for 30 days post-event. Hologic is dedicated to enhancing women’s health through early detection and treatment innovations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
-
Rhea-AI Summary

Hologic, Inc. (NASDAQ: HOLX) announced that the U.S. Court of Appeals for the Federal Circuit upheld a 2021 ruling that invalidated a Minerva patent related to its NovaSure system. The court determined Minerva's patent was invalid due to a delay in filing after showcasing a prototype. This decision aligns with the previous district court judgment, which favored Hologic just before trial. In a related case, Minerva was ordered to pay Hologic over $7.4 million for infringing a Hologic patent. NovaSure, approved by the FDA in 2001, is a minimally invasive procedure for treating abnormal uterine bleeding, with a 77.7% efficacy rate and 92.8% patient satisfaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
Rhea-AI Summary

Hologic Inc. announced the approval of its NovaSure® V5 global endometrial ablation device in Canada and Europe. This advanced version features enhanced technology aimed at treating diverse cervical and uterine anatomies, enhancing patient outcomes. With over 3 million women treated globally, the NovaSure V5 offers a 97% patient satisfaction rate and an 87% hysterectomy avoidance rate at ten years post-procedure. Key improvements include an updated cervical seal and enhanced accuracy markings. The company emphasizes ongoing commitment to innovation in women's health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
Rhea-AI Summary

Hologic, Inc. reported Q1 FY2023 revenue of $1,074 million, surpassing guidance of $940 to $990 million, despite a 27% year-over-year decline primarily due to lower COVID-19 assay sales and semiconductor supply chain issues. GAAP diluted EPS stood at $0.75, down 61.5% from the prior year, with non-GAAP EPS of $1.07, a 50.7% decline. The company experienced a 15.8% revenue growth in Diagnostics, excluding COVID-19, and Surgical revenue grew by 14.7%. Hologic raised its fiscal 2023 revenue guidance to $3.85 billion - $4 billion and EPS guidance to $2.69 - $2.99, indicating confidence in growth despite challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
-
Rhea-AI Summary

Hologic, Inc. (HOLX) reported preliminary revenue results for Q1 FY2023, estimating revenues of approximately $1,074.2 million, exceeding guidance of $940 to $990 million. This represents a 27.0% decline compared to the previous year. However, organic growth in segments excluding COVID was notable: 15.8% in Diagnostics, 24.5% in Molecular Diagnostics, and 14.7% in Surgical. Non-GAAP EPS is expected to exceed the guidance of $0.80 to $0.90. Full financial results will be disclosed on February 1, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
Rhea-AI Summary

Hologic, Inc. (NASDAQ: HOLX) will announce its financial results for Q1 FY2023 on February 1, after market closure. A conference call will follow at 4:30 PM ET. Interested parties can participate via phone or by accessing the webcast on Hologic's investor relations website. A replay will be available for 30 days. Hologic focuses on enhancing women's health through innovative medical technology solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
-
Rhea-AI Summary

Hologic, Inc. (NASDAQ: HOLX) announced its upcoming presentation at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. Pacific Time. The event will include a live webcast accessible on Hologic's Investors website, which will remain available for 30 days post-event. Hologic focuses on enhancing women's health through innovative medical technologies, emphasizing early detection and treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
conferences
-
Rhea-AI Summary

Hologic, Inc. (NASDAQ: HOLX) has appointed Stacey D. Stewart to its Board of Directors and the Audit and Finance Committee, effective January 2, 2023. Ms. Stewart, who has been the President and CEO of March of Dimes since November 2016, is set to depart from the organization by year-end. With a strong background in finance and healthcare, her appointment is expected to enhance the operational expertise of the board. Chairman Steve MacMillan emphasized her experience with purpose-driven organizations as a significant asset for Hologic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
management
Rhea-AI Summary

Hologic and its subsidiary Biotheranostics announced groundbreaking results at the 2022 San Antonio Breast Cancer Symposium, revealing that the Breast Cancer Index test effectively predicts treatment benefits from ovarian function suppression for premenopausal patients with early-stage HR+ breast cancer. The test identified 58% of patients who benefitted from combining ovarian function suppression with endocrine therapy, showing a significant absolute benefit of 11.6%. This data supports the test's role in personalized treatment approaches in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
none

FAQ

What is the current stock price of Hologic (HOLX)?

The current stock price of Hologic (HOLX) is $72.5 as of December 23, 2024.

What is the market cap of Hologic (HOLX)?

The market cap of Hologic (HOLX) is approximately 16.3B.

What does Hologic Inc. specialize in?

Hologic Inc. specializes in developing, marketing, and servicing innovative and accurate diagnostic imaging systems and surgical products, with a focus on women's healthcare.

Where is Hologic Inc. headquartered?

Hologic Inc. is headquartered in Bedford, Massachusetts.

What are the main segments of Hologic’s business?

Hologic operates in five main segments: diagnostics, breast health, surgical, and skeletal health.

Which segment contributes the most to Hologic's revenue?

The diagnostics segment contributes the most, accounting for 60% of Hologic's total sales.

How has the pandemic affected Hologic’s business segments?

The pandemic boosted the diagnostics segment but initially suppressed the breast health segment.

What percentage of Hologic’s revenue comes from the United States?

69% of Hologic’s revenue comes from the United States.

How did the acquisition of Gen-Probe impact Hologic?

The acquisition of Gen-Probe shifted Hologic’s focus more towards commercial diagnostics.

How can I stay updated with Hologic's latest news?

You can stay updated by visiting Hologic's website, or following them on Facebook and Twitter.

What is Hologic’s approach to healthcare?

Hologic is dedicated to the science of sure, providing greater confidence and peace of mind in medical diagnosis to enable healthier lives.

What percentage of Hologic’s revenue comes from international markets?

Approximately 31% of Hologic’s revenue comes from international markets, including Europe, Asia, and other regions.

Hologic Inc

Nasdaq:HOLX

HOLX Rankings

HOLX Stock Data

16.27B
225.10M
0.8%
105.31%
1.98%
Medical Instruments & Supplies
X-ray Apparatus & Tubes & Related Irradiation Apparatus
Link
United States of America
MARLBOROUGH